source
- Vanda halts Novartis-originated social anxiety drug after Phase 3 missVanda Pharmaceuticals announced it is suspending development of VQW-765, a social anxiety disorder candidate licensed from Novartis, after the drug failed to demonstrate a statistically significant…
- Vanda pauses social anxiety program after Phase 3 trial misses endpoint in womenVanda Pharmaceuticals announced Wednesday that it is halting development of its social anxiety disorder candidate after a late-stage trial did not achieve its primary goal. The experimental drug,…